ArticleJournal of oncology2022

A Risk Model Based on Sorafenib-Response Target Genes Predicts the Prognosis of Patients with HCC.

Xiang Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.